Question

A patient is diagnosed with hepatocellular carcinoma (HCC) measuring 5 cm. What is the treatment of choice?

• A. TACE
• B. Sorafenib
• C. Transplant
• D. Palliation

Hint:

HCC Treatment Basics (BCLC):
Very Early/Early: Resection or RFA.
Intermediate (Large/Multinodular, no vascular invasion): TACE.
Advanced (Portal vein invasion or metastases): Sorafenib Atezolizumab+Bevacizumab.

Answer 1

The Correct Option is A

Concept:
A patient is newly diagnosed with a single, substantial Hepatocellular Carcinoma (HCC) nodule measuring 5 cm in diameter.
The clinical task requires navigating the standard treatment algorithms (primarily the Barcelona Clinic Liver Cancer or BCLC criteria) to identify the most universally applicable, standard-of-care initial therapeutic modality for a tumor of this specific size, especially when nuanced details like Child-Pugh class are omitted.
Explanation:
• The treatment algorithm for Hepatocellular Carcinoma is highly complex and depends heavily on three main pillars: tumor burden (size and number of nodules), underlying liver function (Child-Pugh score), and patient performance status, largely guided by the BCLC staging system.

• Very early and early-stage HCC (single nodules typically $< 2-3$ cm with preserved liver function) are optimally treated with curative intent via surgical resection or percutaneous Radiofrequency Ablation (RFA).

• A single tumor measuring precisely 5 cm falls exactly at the upper mathematical limit of the famous Milan criteria (which allows for one lesion $\le 5$ cm) for potential liver transplantation. However, immediate transplantation (Option C) is rarely the immediate "treatment of choice" due to massive organ shortages, long waiting lists, and the strict requirement for perfect criteria matching.

• Tumors that are large (like a 5 cm mass), multinodular, or in patients who are not candidates for immediate surgical resection, yet still lack extrahepatic spread or macroscopic vascular invasion, are generally classified as intermediate-stage HCC.

• For intermediate-stage HCC, Transarterial Chemoembolization (TACE) (Option A) is widely established as the primary standard of care.

• TACE exploits the unique dual vascular supply of the liver; because HCC is almost exclusively fed by the hepatic artery (unlike normal parenchyma which uses the portal vein), embolizing the arterial supply while locally delivering high-dose chemotherapy selectively targets and kills the tumor while sparing the rest of the liver.

• TACE is also heavily used as a "bridge to transplant" for a 5 cm tumor to ensure it does not grow beyond the Milan criteria while the patient waits for a donor organ.

• Systemic therapy with tyrosine kinase inhibitors like Sorafenib (Option B) is strictly reserved for advanced-stage disease (characterized by portal vein invasion or extrahepatic metastasis).

• Palliation/best supportive care (Option D) is reserved for terminal stage disease (Child-Pugh C with poor performance status).
Final Answer:
For a large 5 cm HCC that often bridges surgical criteria, Transarterial Chemoembolization (TACE) serves as the primary standard-of-care locoregional intervention.